Cargando…

Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma

SIMPLE SUMMARY: Targeting BCL-2 through venetoclax is an effective therapy for a series of hematological cancers, such as mantle cell lymphoma (MCL), but resistance to venetoclax is an increasing challenge that needs to be overcome. In order to elucidate the resistance mechanisms to venetoclax in MC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Granau, Agnete Marie, Andersen, Pilar Aarøe, Jakobsen, Theresa, Taouxi, Konstantina, Dalila, Nawar, Mogensen, Johanne Bay, Kristensen, Lasse Sommer, Grønbæk, Kirsten, Dimopoulos, Konstantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856512/ https://www.ncbi.nlm.nih.gov/pubmed/36672458 http://dx.doi.org/10.3390/cancers15020510

Ejemplares similares

P1246: DIFFERENTIAL ROLE OF MICROENVIRONMENT AND STROMAL-CELL INDUCED VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA
por: Andersen, P., et al.
Publicado: (2022)

P1259: CHARACTERIZATION OF VENETOCLAX RESISTANCE IN CELL MODELS OF MANTLE CELL LYMPHOMA
por: Granau, A., et al.
Publicado: (2022)

Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells
por: Jakobsen, Theresa, et al.
Publicado: (2021)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
por: Liu, Yang, et al.
Publicado: (2022)

Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy
por: Dahl, Mette, et al.
Publicado: (2018)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner
por: Dimopoulos, Konstantinos, et al.
Publicado: (2017)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma
por: Kristensen, Lasse Sommer, et al.
Publicado: (2014)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia
por: Przedborski, Michelle, et al.
Publicado: (2022)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response
por: Yuan, Sheng, et al.
Publicado: (2023)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
por: Leshchenko, Violetta V., et al.
Publicado: (2015)

Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
por: Manni, Sabrina, et al.
Publicado: (2022)

Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients
por: Søgaard Helbo, Alexandra, et al.
Publicado: (2015)

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes
por: Fischer, Melissa A., et al.
Publicado: (2022)

Inhibition of VEGFR2 overcomes venetoclax-resistance in diffuse large B-cell lymphoma cells
por: Shi, Yuanfei, et al.
Publicado: (2022)

Tic-tac sans tac-tic
Publicado: (1999)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma
por: Kristensen, Lasse Sommer, et al.
Publicado: (2016)

TicTimer software for measuring tic suppression
por: Black, Jonathan K., et al.
Publicado: (2017)

DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas
por: Michaelsen, Signe Regner, et al.
Publicado: (2018)

Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies
por: Dahl, Mette, et al.
Publicado: (2018)

AML-337: Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy
por: Chang, Kyung Hee, et al.
Publicado: (2020)

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
por: Nishida, Yuki, et al.
Publicado: (2023)

Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations
por: Aslan, Derya, et al.
Publicado: (2016)

3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma
por: Feng, Min, et al.
Publicado: (2021)

Patterns and Predictors of Tic Suppressibility in Youth With Tic Disorders
por: Conelea, Christine A., et al.
Publicado: (2018)

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
por: Avsec, Damjan, et al.
Publicado: (2022)

Convulsive Tic
Publicado: (1905)

Convulsive Tic
Publicado: (1909)

Tics and Their Treatment
Publicado: (1908)

Cannot write session to /tmp/vufind_sessions/sess_b8vbd697knh2hbpfvtt8nfvq3b